Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N Callandar

Primary Therapy With Single Agent Bortezomib as Induction, Maintenance and Re-Induction in Patients With High-Risk Myeloma: Results of the ECOG E2A02 Trial

Leukemia

English

Related publications

Bortezomib Just for Induction or Also for Maintenance in Myeloma Patients With Renal Impairment?

Haematologica

Hematology

2014

English

Efficacy and Safety of Reduced-Intensity Induction Therapy With a Bortezomib-Based Regimen in Elderly Patients With Multiple Myeloma

Therapeutic Advances in Hematology

Hematology

2012

English

Cytogenetic Features and Clinical Outcomes of Patients With Non-Secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy

Clinical Lymphoma, Myeloma and Leukemia

English

Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison

European Journal of Haematology

Medicine

Hematology

2007

English

Induction Therapy and Stem Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

Stem Cells International

Cell Biology

Molecular Biology

2012

English

Peripheral Neuropathy Induced by Subcutaneous Bortezomib-Based Induction Therapy for Newly Diagnosed Multiple Myeloma

Haematologica

Hematology

2014

English

Fatal Cardiovascular Collapse Following Propofol Induction in High-Risk Patients and Dilemmas in the Selection of a Short-Acting Induction Agent

Anaesthesia and Intensive Care

Critical Care

Anesthesiology

Pain Medicine

Intensive Care Medicine

1995

English

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

English

ADE as Induction Therapy Results in Treatment of Children With Non-M3 High-Risk Acute Myeloid Leukemia, an Extrapolable Achievement in Developing Countries

Journal of Cancer Therapy

2016

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by N Callandar

Primary Therapy With Single Agent Bortezomib as Induction, Maintenance and Re-Induction in Patients With High-Risk Myeloma: Results of the ECOG E2A02 Trial

Related publications

Bortezomib Just for Induction or Also for Maintenance in Myeloma Patients With Renal Impairment?

Efficacy and Safety of Reduced-Intensity Induction Therapy With a Bortezomib-Based Regimen in Elderly Patients With Multiple Myeloma

Cytogenetic Features and Clinical Outcomes of Patients With Non-Secretory Multiple Myeloma in the Era of Novel Agent Induction Therapy

Efficacy of Single-Agent Bortezomib vs. Single-Agent Thalidomide in Patients With Relapsed or Refractory Multiple Myeloma: A Systematic Comparison

Induction Therapy and Stem Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

Peripheral Neuropathy Induced by Subcutaneous Bortezomib-Based Induction Therapy for Newly Diagnosed Multiple Myeloma

Fatal Cardiovascular Collapse Following Propofol Induction in High-Risk Patients and Dilemmas in the Selection of a Short-Acting Induction Agent

Final Overall Survival Results of a Randomized Trial Comparing Bortezomib Plus Pegylated Liposomal Doxorubicin With Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

ADE as Induction Therapy Results in Treatment of Children With Non-M3 High-Risk Acute Myeloid Leukemia, an Extrapolable Achievement in Developing Countries